TY  - JOUR
AU  - Torrente-Lopez, Anabel
AU  - Hermosilla, Jesus
AU  - Perez-Robles, Raquel
AU  - Salmeron-Garcia, Antonio
AU  - Cabeza, Jose
AU  - Navas, Natalia
PY  - 2022
DO  - 10.1016/j.microc.2022.107896
SN  - 0026-265X
UR  - http://hdl.handle.net/10668/22392
T2  - Microchemical journal
AB  - Nivolumab (Opdivo (R)) is a fully human immunoglobulin G4 isotype approved for the treatment of many cancers. It acts as an immune checkpoint inhibitor by blocking the interaction between PD-1 (Programmed Cell Death Protein 1) - an inhibitory receptor...
LA  - en
PB  - Elsevier
KW  - UV
KW  - MS data combined use
KW  - Quantification
KW  - Isoform profile identification
KW  - Nivolumab
KW  - LC-MS
KW  - Size-exclusion chromatography
KW  - Cell lung-cancer
KW  - Monoclonal-antibody
KW  - Mass-spectrometry
KW  - Exchange chromatography
KW  - Liquid-chromatography
KW  - Validation
KW  - Proteins
KW  - Light
KW  - Humans
KW  - Nivolumab
KW  - Immune Checkpoint Inhibitors
KW  - Programmed Cell Death 1 Receptor
KW  - B7-H1 Antigen
KW  - Chromatography, High Pressure Liquid
KW  - Molecular Weight
KW  - Temperature
KW  - Neoplasms
KW  - Immunoglobulin G
KW  - Immunoproteins
KW  - Protein Isoforms
KW  - Polysaccharides
KW  - Pharmaceutical Preparations
KW  - T-Lymphocytes
TI  - Combined use of UV and MS data for ICH Stability-Indication Method: Quantification and isoforms identification of intact nivolumab
TY  - research article
VL  - 182
ER  -